HomeQuestion

For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?

In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?

In patients with IV NSCLC and EGFR mutation, is there a cutoff on the % of allele frequency that is considered to be too low to be actionable?

What would you offer to a patient with musculoskeletal pain from tarlatamab, requiring hospitalization and opioid use?

How do you counsel eligible patients on lung cancer screening who are hesitant because of the cancer risk from CT scans?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.